This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ikeda, H. Articles by Imaizumi, T. Search for Related Content PubMed PubMed Citation Articles by Ikeda, H. Articles by Imaizumi, T. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB NITRIC OXIDE Related Collections Risk Factors Platelets

(Hypertension. 2000;35:904.)
© 2000 American Heart Association, Inc.

Scientific Contributions

Platelet-Derived Nitric Oxide and Coronary Risk Factors

Hisao Ikeda; Yoshinori Takajo; Toyoaki Murohara; Kazuya Ichiki; Hisashi Adachi; Nobuya Haramaki; Atsushi Katoh; Tsutomu Imaizumi

From the Department of Internal Medicine III (H.I., Y.T., K.I., H.A., N.H., A.K., T.I.) and Cardiovascular Research Institute (T.M.), Kurume University School of Medicine, Kurume, Japan.

Correspondence to Hisao Ikeda, MD, PhD, Department of Internal Medicine III, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan. E-mail ikeikeda{at}med.kurume-u.ac.jp

Abstract—Platelet aggregation is inhibited through a negative feedback mechanism by the L-arginine/nitric oxide (NO) pathway found in platelets themselves. We have shown that long-term smoking impairs the bioactivity of platelet-derived NO (PDNO), resulting in an increased platelet aggregability. However, little is known about the relation between other coronary risk factors and PDNO release. Accordingly, this study was undertaken to examine whether other coronary risk factors are related to the impairment of PDNO bioactivity. We measured collagen-induced PDNO release with an NO-selective electrode in 61 subjects (mean age 47 years, range 24 to 74 years) who underwent complete physical and laboratory examinations. There was a significant inverse correlation between PDNO release and the number of coronary risk factors (r=-0.61, P<0.001). Univariate analysis showed a significant inverse correlation between PDNO release and age (r=-0.33, P<0.01), mean arterial pressure (r=-0.40, P<0.002), total cholesterol level (r=-0.31, P<0.02), and LDL-cholesterol level (r=-0.33, P<0.02). PDNO release was significantly lower in long-term smokers than in nonsmokers (P<0.001). With multiple stepwise regression analysis, PDNO release correlated significantly and independently (r²=0.51), with smoking (F=37.8), age (F=7.1), and mean arterial pressure (F=5.1). Thus, we demonstrated that coronary risk factors are associated with an impairment of PDNO release by human platelets. Our findings may contribute to the understanding of the pathophysiological link between coronary risk factors and atherothrombotic disease.

Key Words: platelets • nitric oxide • risk factors • atherothrombosis

This article has been cited by other articles:

				E. Gkaliagkousi, J. Ritter, and A. Ferro Platelet-Derived Nitric Oxide Signaling and Regulation Circ. Res., September 28, 2007; 101(7): 654 - 662. [Abstract] [Full Text] [PDF]

				N. Haramaki, H. Ikeda, K. Takenaka, A. Katoh, R. Sugano, S.-i. Yamagishi, H. Matsuoka, and T. Imaizumi Fluvastatin Alters Platelet Aggregability in Patients With Hypercholesterolemia: Possible Improvement of Intraplatelet Redox Imbalance via HMG-CoA Reductase Arterioscler Thromb Vasc Biol, June 1, 2007; 27(6): 1471 - 1477. [Abstract] [Full Text] [PDF]

				M. Jayachandran, R. Mukherjee, T. Steinkamp, P. LaBreche, M. P. Bracamonte, H. Okano, W. G. Owen, and V. M. Miller Differential effects of 17{beta}-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2355 - H2362. [Abstract] [Full Text] [PDF]

				A. Natali, S. Baldeweg, E. Toschi, B. Capaldo, D. Barbaro, A. Gastaldelli, J. S. Yudkin, and E. Ferrannini Vascular Effects of Improving Metabolic Control With Metformin or Rosiglitazone in Type 2 Diabetes Diabetes Care, June 1, 2004; 27(6): 1349 - 1357. [Abstract] [Full Text] [PDF]

				S. Tsiara, M. Elisaf, and D. P. Mikhailidis Influence of Smoking on Predictors of Vascular Disease Angiology, September 1, 2003; 54(5): 507 - 530. [Abstract] [PDF]

				L. J. Dixon, D. R. Morgan, S. M. Hughes, L. T. McGrath, N. A. El-Sherbeeny, R. D. Plumb, A. Devine, W. Leahey, G. D. Johnston, and G. E. McVeigh Functional Consequences of Endothelial Nitric Oxide Synthase Uncoupling in Congestive Cardiac Failure Circulation, April 8, 2003; 107(13): 1725 - 1728. [Abstract] [Full Text] [PDF]

				M. Jayachandran and V. M. Miller Ovariectomy upregulates expression of estrogen receptors, NOS, and HSPs in porcine platelets Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H220 - H226. [Abstract] [Full Text] [PDF]

				A. J. Taylor, A. Bobik, M. C. Berndt, D. Ramsay, and G. Jennings Experimental Rupture of Atherosclerotic Lesions Increases Distal Vascular Resistance: A Limiting Factor to the Success of Infarct Angioplasty Arterioscler Thromb Vasc Biol, January 1, 2002; 22(1): 153 - 160. [Abstract] [Full Text] [PDF]

				Y. Y. Chirkov, A. S. Holmes, S. R. Willoughby, S. Stewart, R. D. Wuttke, P. R. Sage, and J. D. Horowitz Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1851 - 1857. [Abstract] [Full Text] [PDF]

				J. Loscalzo Nitric Oxide Insufficiency, Platelet Activation, and Arterial Thrombosis Circ. Res., April 27, 2001; 88(8): 756 - 762. [Abstract] [Full Text] [PDF]